The heterogeneity of lipid metabolism in cancer

Abstract

Fatty acid synthesis is upregulated in cancer.The mitochondrial citrate transporter protein (CTP) protects mitochondrial function in cancer.ATP citrate lyase (ACLY) is upregulated in cancer.Multifaceted effects of inhibiting acetyl-CoA carboxylase (ACC) in cancer.First fatty acid synthase (FAS) inhibitor TVB-2640 in clinical trials for cancer.What markers can predict cancer cell sensitivity to lipid synthesis inhibition?Tumor microenvironment impacts the sensitivity of cancer cells to lipid synthesis inhibitors.The efficacy of inhibiting cholesterol synthesis with adjuvant statins is variable.Fatty acid uptake is associated with metastasis.Targeting FAO for cancer therapy may be achieved by inhibiting carnitine palmitoyltransferase 1.Carnitine palmitoyltransferase 1 (CPT1) inhibitors are now in clinical trials. FAO occurs at the peroxisome where peroxisome proliferator-activated receptors (PPARs) act as ligand-activated transcription factors.